Euesden, J.; Gowrisankar, S.; Qu, A.X.; St. Jean, P.; Hughes, A.R.; Pulford, D.J.
Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting. Genes 2020, 11, 501.
https://doi.org/10.3390/genes11050501
AMA Style
Euesden J, Gowrisankar S, Qu AX, St. Jean P, Hughes AR, Pulford DJ.
Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting. Genes. 2020; 11(5):501.
https://doi.org/10.3390/genes11050501
Chicago/Turabian Style
Euesden, Jack, Sivakumar Gowrisankar, Angela Xiaoyan Qu, Pamela St. Jean, Arlene R. Hughes, and David J. Pulford.
2020. "Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting" Genes 11, no. 5: 501.
https://doi.org/10.3390/genes11050501
APA Style
Euesden, J., Gowrisankar, S., Qu, A. X., St. Jean, P., Hughes, A. R., & Pulford, D. J.
(2020). Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting. Genes, 11(5), 501.
https://doi.org/10.3390/genes11050501